Luxsol™ Test Facility

Texas Biomedical Research Institute. Texas Biomedical Research Institute is the only privately-owned facility that has both BSL3 and BSL4 in the United States.

3V Medical Research Group, developed a targeted therapeutic therapy treatment for SARs CoV-2 infection and Influenza.

3V Medical preformed in vitro and in vivo studies at Texas Biomedical Research Institute located in San Antonio, Texas.

In Vitro and In Vivo Study Design and Results

In Vitro Study Assessment of the Effect of 3VM1000 Suspension on SARS-CoV-2 Infectivity.


The purpose of this study is to assess the effect of 3VM1000 Suspension on SAR CoV-2 infectivity of host cells in vitro. Pre-challenge study to determine if 3VM100 Suspension is effective in killing SARS-CoV-2 and reduce its infectivity in vitro.

SOW (Click here)
Final In Vitro Study test report (Click here)

In Vivo Study To determine the anti-SARS-CoV-2 effect of 3VM-1000 suspension in K18 hACE‑2 mice.


This study is designed to test in vivo toxicity and efficacy of 3VM-1000 suspension in a mouse
model of SARS-CoV-2 infection by measuring the viral load and survival. To determine the anti-SARS-CoV-2 effect of 3VM-1000 suspension in K18 hACE-2 mice.

Aim 1: To determine in vivo toxicity of 3VM-1000 suspension solution in K18-hACE-2 mice

SOW (click here)
Final Results (click here)

Aim 2: In vivo
assessment of 3VM-1000 suspension on SARS-CoV-2 infectivity

Currently, Texas Biomedical Research Institute is conducting Aim 2 study using 3VM-1000 suspension solution for the effectiveness to treat SARS-CoV2.